Last Updated on August 24, 2022 by GlobeNewsWire
Leuven, BELGIUM, Boston, MA, US – August 24, 2022 – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced that it will participate in three upcoming conferences.
22ndEURETINA Congress – Hamburg, GermanyDate: Friday, September 2, 2022 11 a.m. ET Tom Graney, CEO of Oxurion, will deliver a virtual presentation and is available for one-on-one meetings.
The presentations will be available in the “Investors” section of the Company’s website.
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at http://www.oxurion.com.
For further information please contact:
Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13 email@example.com
Michael DillenChief Business OfficerTel: +32 479 firstname.lastname@example.org
USConway CommunicationsBeth Kurthbkurth@conwaycommsir.com
ICR WestwickeChristopher BrinzeyTel: +1 617 835 9304Chris.Brinzey@westwicke.com